Phase 3 Studies of Pirfenidone for Idiopathic Pulmonary Fibrosis - ONA
Links shared publicly online about this topic.
- 289total visits
Phase 3 Studies of Pirfenidone for Idiopathic Pulmonary Fibrosis - ONA
View full resource at oncologynurseadvisor.com
Tags: Pulmonary Fibrosis, Phase 3 Clinical Trial, Pulmonology
Most Recently Shared on May 16, 2011 at 3:47 pm By:
Phase 3 Studies of Pirfenidone for Idiopathic Pulmonary Fibrosis http://goo.gl/fb/vWdYN
InterMune Initiates Phase 3 ASCEND Study Of Pirfenidone In IPF - QualityPoint Technologies
qualitypointtech.net — “InterMune (NASDAQ: ITMN) announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF). ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function. The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) fro” View full resource at qualitypointtech.net
Most Recently Shared on July 9, 2011 at 11:00 am By:
InterMune Initiates Phase 3 ASCEND Study Of Pirfenidone In IPF: InterMune (NASDAQ: ITMN) announced that patient en... http://bit.ly/mS6WOK
Phase 3 Studies of Pirfenidone for Idiopathic Pulmonary Fibrosis - MPR
empr.com — “InterMune announced positive data from its CAPACITY Program studying pirfenidone for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF).” View full resource at empr.com
Most Recently Shared on May 16, 2011 at 3:32 pm By:
MPR News: Phase 3 Studies of Pirfenidone for Idiopathic Pulmonary Fibrosis: InterMune announced positive data fr... http://bit.ly/jgTAOZ
The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis
news-medical.net — “InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).” View full resource at news-medical.net
Most Recently Shared on May 16, 2011 at 4:38 am By:
The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis: InterMune, Inc. tod... http://bit.ly/kKfLww
Advertisement
